European Pharmaceutical Review

SEPTEMBER 29, 2023

of the draft revised Community Code provides a reduction in the basic data exclusivity period for innovative medicinal products from eight to six years, a revision which did not come as a great surprise to many. As an example, Article 81.1 The European Commission has evidently expended significant effort in developing the proposals.

Communication 98

Communication Hospitals Vaccines 98

pharmaphorum

MARCH 12, 2021

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase.

Vaccines 111

Vaccines Communication Pharmaceutical Companies Pharmaceutical Companies 111

Pharmaceutical Technology

MARCH 22, 2023

During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Communication Immunity 52

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Vaccines 98

Vaccines Communication 98

ID Stewardship

MARCH 7, 2025

In this article a clinical infectious diseases pharmacist reviews five things for pharmacists to know about measles in 2025. Although I have practiced in the area of infectious diseases pharmacy for quite a while now, measles has not been of much clinical relevance to me beyond MMR for routine vaccination. Authored By: Timothy P.

Vaccines 119

Vaccines Immunity Immunization Communication 119

Putting Patients First Blog

SEPTEMBER 9, 2024

CY 2025 PFS proposed rule). The continuation of audio-only communication options remains essential. Preventive Services The expansion of preventive services, including hepatitis B vaccinations and colorectal cancer screenings, is a positive development for public health.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Documentation Vaccines Communication 40

Express Pharma

JANUARY 20, 2025

By fulfilling about 20 per cent of the global generic drug supply by volume and producing 60 per cent of the worlds vaccines, India now stands as a global leader in affordable medicines and vaccines. Our commitment to accessible healthcare has led to transformative change.

Communication 105

Communication Vaccines 105